• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨肉瘤中肿瘤内在免疫逃逸基因的分子特征表明其预后和肿瘤微环境浸润。

Molecular characterization of cancer-intrinsic immune evasion genes indicates prognosis and tumour microenvironment infiltration in osteosarcoma.

机构信息

Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

Institute of Orthopedics of Jiangxi, Nanchang, Jiangxi 330006, China.

出版信息

Aging (Albany NY). 2023 Oct 4;15(19):10272-10290. doi: 10.18632/aging.205074.

DOI:10.18632/aging.205074
PMID:37796192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10599718/
Abstract

Cancer-intrinsic immune evasion (IE) to cells is a critical factor in tumour growth and progression, yet the molecular characterization of IE genes (IEGs) in osteosarcoma remains underexplored. In this study, 85 osteosarcoma patients were comprehensively analyzed based on 182 IEGs, leading to the identification of two IE clusters linked to distinct biological processes and clinical outcomes. In addition, two IE clusters demonstrated diverse immune cell infiltration patterns, with IEGcluster A displaying increased levels compared to IEGcluster B. Moreover, an IE score was identified as an independent prognostic factor and nomogram may serve as a practical tool for the individual prognostic evaluation of patients with osteosarcoma. Finally, GBP1, a potential biomarker with high expression in osteosarcoma was identified. The findings of this study highlight the presence of two IE clusters, each associated with differing patient outcomes and immune infiltration properties. The IE score may serve to assess individual patient IE characteristics, enhance comprehension of immune features, and guide more efficacious treatment approaches.

摘要

肿瘤内在免疫逃逸（IE）是肿瘤生长和进展的关键因素，但骨肉瘤中 IE 基因（IEGs）的分子特征仍未得到充分探索。在这项研究中，对 85 名骨肉瘤患者进行了全面分析，共涉及 182 个 IEGs，从而确定了与不同生物学过程和临床结局相关的两个 IE 簇。此外，两个 IE 簇表现出不同的免疫细胞浸润模式，IEGcluster A 的水平较 IEGcluster B 升高。此外，IE 评分被确定为独立的预后因素，列线图可能成为骨肉瘤患者个体化预后评估的实用工具。最后，鉴定到一个在骨肉瘤中高表达的潜在生物标志物 GBP1。本研究的结果表明存在两个 IE 簇，每个簇都与不同的患者结局和免疫浸润特征相关。IE 评分可用于评估个体患者的 IE 特征，增强对免疫特征的理解，并指导更有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/4cf60087e4e1/aging-15-205074-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/7a9e75887b74/aging-15-205074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/04f155799807/aging-15-205074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/54d5b3908a57/aging-15-205074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/581a5f7d2c72/aging-15-205074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/ba475c4ced11/aging-15-205074-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/d1598954eacd/aging-15-205074-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/cd188825976b/aging-15-205074-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/4cf60087e4e1/aging-15-205074-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/7a9e75887b74/aging-15-205074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/04f155799807/aging-15-205074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/54d5b3908a57/aging-15-205074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/581a5f7d2c72/aging-15-205074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/ba475c4ced11/aging-15-205074-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/d1598954eacd/aging-15-205074-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/cd188825976b/aging-15-205074-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/206c/10599718/4cf60087e4e1/aging-15-205074-g008.jpg

相似文献

1
Molecular characterization of cancer-intrinsic immune evasion genes indicates prognosis and tumour microenvironment infiltration in osteosarcoma.骨肉瘤中肿瘤内在免疫逃逸基因的分子特征表明其预后和肿瘤微环境浸润。
Aging (Albany NY). 2023 Oct 4;15(19):10272-10290. doi: 10.18632/aging.205074.
2
Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways.基于代谢途径探讨骨肉瘤中代谢与免疫微环境的关系。
J Biomed Sci. 2024 Jan 12;31(1):4. doi: 10.1186/s12929-024-00999-7.
3
Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.骨肉瘤患者预后肿瘤微环境相关基因的综合分析。
BMC Cancer. 2020 Aug 27;20(1):814. doi: 10.1186/s12885-020-07216-2.
4
Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.鉴定和特征分析骨肉瘤中与衰老/衰老相关的基因，并预测临床预后。
Front Immunol. 2022 Oct 5;13:997765. doi: 10.3389/fimmu.2022.997765. eCollection 2022.
5
Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.免疫原性细胞死亡的分子特征表明骨肉瘤的预后和肿瘤微环境浸润。
Front Immunol. 2022 Dec 9;13:1071636. doi: 10.3389/fimmu.2022.1071636. eCollection 2022.
6
Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.基于癌症干细胞相关基因的骨肉瘤分子亚型可定义免疫细胞浸润和患者生存情况。
Front Immunol. 2022 Aug 19;13:986785. doi: 10.3389/fimmu.2022.986785. eCollection 2022.
7
A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.骨肉瘤肿瘤微环境中免疫浸润的综合分析。
Cancer Med. 2021 Aug;10(16):5696-5711. doi: 10.1002/cam4.4117. Epub 2021 Jul 13.
8
Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma.失巢凋亡模式在骨肉瘤中呈现出不同的预后和免疫格局。
Int Immunopharmacol. 2023 Feb;115:109684. doi: 10.1016/j.intimp.2023.109684. Epub 2023 Jan 9.
9
The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.骨肉瘤中m1A/m5C/m6A相关lncRNA特征的预后价值及免疫图谱
Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5868-5883. doi: 10.26355/eurrev_202208_29526.
10
A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.一种预测骨肉瘤预后和指导治疗的新型免疫细胞特征。
Front Immunol. 2022 Sep 14;13:1017120. doi: 10.3389/fimmu.2022.1017120. eCollection 2022.

引用本文的文献

1
Comprehensive analysis of gene expression profiles of annulus fibrosus subtypes and hub genes in intervertebral disc degeneration.全面分析纤维环亚型和椎间盘退变中枢纽基因的基因表达谱。
Aging (Albany NY). 2024 Mar 13;16(6):5370-5386. doi: 10.18632/aging.205653.

本文引用的文献

1
CD8 + T-cell marker genes reveal different immune subtypes of oral lichen planus by integrating single-cell RNA-seq and bulk RNA-sequencing.CD8+T 细胞标记基因通过整合单细胞 RNA-seq 和批量 RNA-seq 揭示口腔扁平苔藓的不同免疫亚型。
BMC Oral Health. 2023 Jul 8;23(1):464. doi: 10.1186/s12903-023-03138-0.
2
NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression.NOP2以依赖EIF3A的方式介导c-Myc的m5C修饰，从而重编程葡萄糖代谢并促进肝细胞癌进展。
Research (Wash D C). 2023 Jun 30;6:0184. doi: 10.34133/research.0184. eCollection 2023.
3
Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes.
颠覆抗肿瘤疗法：释放 B 细胞来源外泌体的潜力。
Front Immunol. 2023 Jun 5;14:1188760. doi: 10.3389/fimmu.2023.1188760. eCollection 2023.
4
A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.一种基于癌相关成纤维细胞的新型标志物可预测肺腺癌的预后和免疫治疗反应。
Front Immunol. 2023 May 31;14:1201573. doi: 10.3389/fimmu.2023.1201573. eCollection 2023.
5
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma.高迁移率族蛋白A1（HMGA1）通过磷脂酰肌醇-3-激酶/雷帕霉素靶蛋白（PI3K/mTOR）信号通路增强肝内胆管癌中帕博西尼的疗效。
Biomark Res. 2023 Mar 29;11(1):33. doi: 10.1186/s40364-023-00473-w.
6
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.调控骨肉瘤的免疫微环境：骨肉瘤治疗的前景
Bone Res. 2023 Feb 27;11(1):11. doi: 10.1038/s41413-023-00246-z.
7
Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.胶质母细胞瘤和帕金森病中神经营养因子相关基因特征的鉴定和验证。
Front Immunol. 2023 Feb 7;14:1090040. doi: 10.3389/fimmu.2023.1090040. eCollection 2023.
8
Construction of a novel mRNAsi-related risk model for predicting prognosis and immunotherapy response in osteosarcoma.构建用于预测骨肉瘤预后和免疫治疗反应的新型mRNAsi相关风险模型。
Ann Transl Med. 2023 Jan 31;11(2):61. doi: 10.21037/atm-22-6011.
9
Exosomes: A potential tool for immunotherapy of ovarian cancer.外泌体：卵巢癌免疫治疗的潜在工具。
Front Immunol. 2023 Jan 18;13:1089410. doi: 10.3389/fimmu.2022.1089410. eCollection 2022.
10
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.克服骨肉瘤免疫治疗耐药的策略。
Int J Mol Sci. 2023 Jan 2;24(1):799. doi: 10.3390/ijms24010799.